Where does NewAmsterdam Pharma Company's cash flow data come from?

Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$212.73M-13.5%	-$203.82M+15.6%	-$221.07M-11.1%	-$165.72M+27.8%	-$187.36M+18.1%
Depreciation and amortization	$230K+53.3%	$220K+94.7%	$212K+183%	$176K+189%	$150K+173%
Stock-based compensation	$62.21M+52.1%	$59.43M+76.8%	$54.82M+81.5%	$47.8M+73.2%	$40.91M+64.5%
Amortization of debt issuance costs	-$882K-29.1%	-$1.41M-519%	-$1.44M—	-$1.1M—	-$683.25K—
Gain (loss) on sale of assets	——	——	——	——	——
Change in accounts payable	$2.26M—	$5.3M—	-$3.22M—	——	——
Change in accrued liabilities	——	——	——	——	——
Change in deferred revenue	——	——	——	——	——
Net cash from operating activities	-$141.92M-1.1%	-$147.78M+6.8%	-$144.39M+6.3%	-$124.12M+34.2%	-$140.43M+14.3%
Capital expenditures	$268K-11.6%	$246K-63.4%	$149K-77.8%	$182K-70.0%	$303K-24.6%
Net cash from investing activities	-$191.79M-222%	-$177.42M-182%	-$218.46M-32,409%	-$218.54M-35,962%	-$59.61M-14,728%
Proceeds from issuance of common stock	$31.96M+246%	$29.47M+1,567%	$18.23M—	$12.67M—	$9.25M—
Net cash from financing activities	$34.07M-92.7%	$29.52M-95.5%	$472.45M+133%	$466.61M+130%	$467.85M+129%
Effect of exchange rate changes on cash	$7.72M+1,542%	$12.82M+288%	$4.88M-23.2%	$9.2M+4,179%	-$535K—
Net increase (decrease) in cash	-$297.13M—	-$293.18M—	$112.1M—	——	——
Income taxes paid	——	——	——	——	——
Non-cash interest expense	-$882K-29.1%	-$1.41M-519%	-$1.44M—	-$1.1M—	-$683.25K—
Change In Fair Value Of Derivative Earnout And Warrants	$30.6M—	$18.78M—	$49.01M—	$25.99M—	——
Foreign currency remeasurement (loss) gain on debt	$7.23M+6,299%	$13.14M+299%	$5.27M-18.8%	$9.73M+821%	$113K+126%
Gain/(loss) on dispositions, net	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	——	——
Deferred revenue	——	——	——	——	——
Increase Decrease In Prepayments And Other Receivables	——	——	——	$15.01M—	$2.38M—
Noncash Rent Expense	——	——	——	——	$14K+180%
Payments Of Stock Issuance Costs	——	——	——	——	——
Proceeds From Warrant Exercises	$2.11M-59.4%	$1.64M-88.1%	$798K-94.1%	$524K-96.1%	$5.18M-65.4%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$7.72M+1,542%	$12.82M+288%	$4.88M-23.2%	$9.2M+4,179%	-$535K—
Issuance Of Earnout Shares Amount	——	——	——	——	——
Recognition Of Rou Asset	——	——	——	——	——
Free cash flow	-$142.19M-1.0%	-$148.03M+7.0%	-$144.54M+6.6%	-$124.3M+34.3%	-$140.73M+14.4%
Free cash flow	-$142.19M-1.0%	-$148.03M+7.0%	-$144.54M+6.6%	-$124.3M+34.3%	-$140.73M+14.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does NewAmsterdam Pharma Company's cash flow data come from?: Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.